First Time Loading...
G

Gemini Therapeutics Inc
NASDAQ:GMTX

Watchlist Manager
Gemini Therapeutics Inc
NASDAQ:GMTX
Watchlist
Price: 19.89 USD 47.33% Market Closed
Updated: May 14, 2024

Gemini Therapeutics Inc
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gemini Therapeutics Inc
Operating Expenses Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
G
Gemini Therapeutics Inc
NASDAQ:GMTX
Operating Expenses
-$47.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Expenses
-$19.5B
CAGR 3-Years
-4%
CAGR 5-Years
-8%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Operating Expenses
-$12.1B
CAGR 3-Years
9%
CAGR 5-Years
-6%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Operating Expenses
-$12.5B
CAGR 3-Years
-7%
CAGR 5-Years
-6%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Expenses
-$4.8B
CAGR 3-Years
-22%
CAGR 5-Years
-19%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Expenses
-$7.3B
CAGR 3-Years
-22%
CAGR 5-Years
-15%
CAGR 10-Years
-19%

See Also

What is Gemini Therapeutics Inc's Operating Expenses?
Operating Expenses
-47.5m USD

Based on the financial report for Dec 31, 2022, Gemini Therapeutics Inc's Operating Expenses amounts to -47.5m USD.

What is Gemini Therapeutics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 1Y
31%

Over the last year, the Operating Expenses growth was 31%.